BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Sacituzumab Govitecan: trial readouts and FDA decisions

2 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 0 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Marengo Therapeutics, Inc., Merck Sharp & Dohme LLC. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P1/P2Marengo Therapeutics, Inc.NCT06827613 A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab GovitTriple Negative Locally Advanced Non-resectable Breast Cancer; HR+, HER2-, Advanced Breast Cancerrecruiting50
2027-01-12 est.P3Merck Sharp & Dohme LLC MRKNCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell LungCarcinoma, Non-Small-Cell Lungactive not recruiting614

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
None in the last 180 days.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.